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Abstract
Brain Derived Neurotrophic Factor (BDNF) is associated with changes in cellular
structure that occur during the development of the nervous system, and in the
adult brain contributes to neural plasticity. BDNF is found in high concentrations
in both the frontal cortex and hippocampus where it has been proposed to play a
role in cognition and learning respectively. Low serum BDNF levels can be
measured in patients with major depressive disorder, and there is a correlation
between decreased BDNF levels and the severity of depression. At this time,
research is attempting to solve the question of whether depression results
secondary to diminished BDNF levels, or a reduction in BDNF levels occurs as a
result of individuals becoming depressed.
Learned Helplessness (LH) is utilized as a model for depression and this is
confirmed due to the fact that LH is blocked by antidepressant medications. An
advantage of using LH to induce depressive behavior is the fact that the onset of
depression in an animal is at a defined time point.

The model of Learned

Helplessness allows for analysis of depressed patients via LH mice which at this
current time is the most accurate model for depression. In this study, our results
were consistent with the hypothesis that since BDNF levels are significantly
reduced in the medial frontal cortices and hippocampus of depressed patients, as
well as in several studies looking at depression in rodents, then BDNF mRNA
levels would also be reduced in the brain tissue of LH mice compared to controls
after induction of Learned Helplessness. We also predicted that the decrease in
the amount of BDNF transcripts would be greater in the medial frontal cortical
region (MFC) compared with hippocampal tissue, since deficits in this region
have been identified in depressed patients. This was also found to be true in this
experiment. The hypothesis was tested by measuring the mRNA message for
the five BDNF transcript variants in both the hippocampus and the medial frontal
cortex in mice that had experienced inescapable unpredicted foot shocks during
learned helplessness training. This data was compared to control mice that did
not experience the Learned Helplessness training. Differences in BDNF mRNA
levels were then determined thereafter. Levels of mRNA BDNF in the HPC and
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MFC of both experimental LH and control animals were quantified using RT-PCR
technique.

Introduction
Brain-derived neurotrophic factor (BDNF) is a neurotrophic factor found
originally in the brain as well as the periphery. BDNF is said to be associated
with changes in cells and plasticity that occur during the development nervous
system, and facilitates the synaptic function in neurons in vitro and in vivo (Lu
and Woo, 2005). BDNF also supports the survival of existing neurons. BDNF is
active in the hippocampus CA2 and CA3 neurons, cortex, cerebellar cortex,
thalamic and hypothalamic nuclei, and the basal forebrain. These include areas
important to learning, memory, and higher thought processes. Expression of
BDNF may also be seen in the retina, the CNS, motor neurons, the kidneys, and
the prostate (Chao, 2003).
BDNF is involved in the expression of many neurotransmitter systems
(Mamounas et al., 1995), amyotrophic lateral sclerosis (Apfel, 1997), Alzheimer
disease (Connor et al., 1997: Durany et al., 2000), schizophrenia (Takahashi et.
al., 2000), and in various forms of major depression (Nibuya et al., 1995).
Findings from Karege et al. (2002) indicate that alteration in the expression of
neurotrophic factors (primarily BDNF) could be the factor responsible for the
interruption of proper neural plasticity. In support of our hypothesis, these
findings suggest that antidepressants increase neurotrophin synthesis and
enhance neurogenesis, thereby relieving the symptoms of depression (Nibuya et
al., 1995; Duman et al., 1997).
Recent studies have given evidence regarding a neurotrophic hypothesis
of antidepressant action on depression (Song et al., 2006). This hypothesis
explains that decreased BDNF expression could play a role in the atrophy of the
hippocampus, which occurs in response to stress in depressed patients. This
allows for a role of BDNF upregulation in the treatment of depression (Duman et.
al., 1997).
The results given in studies conducted by Song et al. (2006) support this
hypothesis in that treatment of antidepressants improve both the changes of
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behavior and hippocampus BDNF levels induced by learned helplessness and
chronic mild stress. Learned helplessness and chronic mild stress were the
damaging factors of cognitive functioning of the mice in this study, but
researchers were able to improve these impairments through the use of
antidepressant treatment. These cognitive changes were consistent with the
alterations of the hippocampal BDNF levels.
BDNF is believed to be involved in several key functions within the brain,
which include: regulation of axonal and dendritic growth and guidance,
neurotransmitter release, and synaptic structure and plasticity. Mature BDNF
also facilitates early phase and late phase long term potentiation in the
hippocampus, the region of the brain which has been shown to have the highest
neuroanatomical expression of BDNF and its TrkB receptor in the mammalian
brain (Lu 2005, Tyler 2002). Patients with major depressive disorder have low
serum BDNF levels, and there is a correlation between decreased BDNF levels
and the severity of depression. BDNF expression in postmortem hippocampus
collected from depressed suicide patients is reduced, whereas it is increased in
individuals who were being treated with antidepressants at the time of death
(Chen et al 2001; Karege et al 2005). These studies in humans are supported by
various studies in rodents (Monteggia et al. 2006). BDNF may even produce an
antidepressant-like effect through the antagonism of learned helplessness
behavior (Karege 2002). Learned Helplessness is a model for depression based
on the hypothesis that depression is induced by uncontrollable stress in
individuals with a predisposition.
Exposure

to

stress

induces

the

stress

hormone

corticosterone.

Corticosterone has been shown to decrease the expression of BDNF in rats, and
leads to atrophy of the hippocampus if exposure is chronic (2). This atrophy may
also take place in humans who suffer from chronic depression. In order to reduce
the expression of BDNF, BDNF heterozygous rats were bred for analysis. These
rats exhibited hippocampal atrophy, which suggests a possible link between the
development of depression and regulation of BDNF. In contrast, glutamate,
exercise, reduction in caloric intake, intellectual stimulation, antidepressants, and
electroconvulsive therapy were used to treat depression, and increased the
expression of BDNF in the brain, which allows for protection against atrophy.
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In mice, BDNF transcripts 1, 2 and 3 are primarily expressed in the central
nervous system, whereas variants 4 and 5 are expressed in both the central
nervous system and peripheral tissues; transcript 6 shows limited expression in
the brain and periphery (Liu et al. 2006). Each of the five BDNF transcripts is
present in mouse hippocampus and frontal cortex, in an apparent rank order:
BDNF5 > BDNF4 > BDNF1 > BDNF2 > BDNF3 in hippocampus and BDNF5 >
BDNF 4 > BNDF3 > BDNF1 > BDNF2 in frontal cortex (Liu et al. 2006). The
function(s) of the individual BDNF transcripts is unknown, although differing
stimuli regulate the production of unique subsets of transcripts.
Acute, but not chronic, cocaine administration increases BDNF4 transcript
in the striatum and frontal cortex (Liu et al. 2006). Chronic (21-day)
corticosterone treatment decreased BDNF transcripts containing exons II and V
(IV in rat) in the hippocampus and frontal cortex, while chronic (21-day, 1X/day)
treatment with desipramine increase transcripts 1 and 4 (3 in rat) in both
hippocampus and frontal cortex (Dwivedi et al. 2006). Phenelzine increases
transcripts containing exon I in both the frontal cortex and hippocampus, but
exon V-containing transcripts only in the hippocampus. Kainate-induced seizures
increase the levels of BDNF transcripts 1, 2, and 4 in hippocampus (Timmusk et
al. 1993).
In the present study, we predict that since BDNF levels are significantly
reduced in the medial frontal cortices and hippocampus of depressed patients, as
well as in several studies looking at depression in rodents, then BDNF mRNA
levels will also be reduced in the brain tissue of LH mice compared to controls
after induction of Learned Helplessness. We further predict that the decrease in
BDNF message will be greater in tissue taken from the medial frontal cortical
region compared with hippocampal tissue due to the role that the MFC plays in
depression; including its involvement in mediating emotional experience, mood,
emotional processing, and the impact of these factors on cognition. To test this
hypothesis, mRNA message for the BDNF transcript variants (I-V) will be
measured in both hippocampus and medial frontal cortex in mice that have
previously experience inescapable shocks during learned helplessness training,
and will be compared to control mice that do not experience the learned
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helplessness training. The mRNA for the BDNF transcripts in the brain will be
quantified using RT-PCR technique.

Methods
C57BL/6J adult mice will be used in these studies.

All of the procedures

involving the animals will be approved by the University of New Mexico
Laboratory Animal Care and Use Committee and will be conducted by a trained
laboratory technician. The laboratory holds currently approved protocols for these
studies. Mice will undergo the learned helplessness (LH) procedure as previously
described by (Caldarone et al. 2000). This procedure is well supported as a test
for assessing and developing depressive behavior. There are two groups; one
undergoes the LH procedure, experiencing 120 inescapable unpredicted
footshocks. The other is a control group that experiences the same apparatus,
although no foot shocks are presented. There will be a minimum of 8 mice from
each of the control and LH groups. One hour following the procedure, the
hippocampus and medial frontal cortices of both groups will be analyzed to
determine any differences in BDNF mRNA levels.

Learned Helplessness
A Coulbourn™ Habitest© shuttlebox with a stainless steel grid floor for
administration of a footshock will be used. The front and back of the box are
made of Plexiglas, and the sides, door, and ceiling are made of aluminum. The
two-chambered box is housed within a sound-attenuated chamber. A 70%
isopropanol solution will be used to clean the apparatus between each mouse
and training/testing period. For the experimental group, one mouse will be placed
in each chamber of the shuttlebox, and a 0.5 mA shock with a duration of 2
seconds and a frequency of approximately every 10 seconds will be administered
through the stainless steel floor to each mouse simultaneously for 1 hour. The
shock will be inescapable and set at a random probability of 0.5 shocks every 15
seconds, and the mouse will be removed 30 seconds after the delivery of the last
shock. For the control group, mice will be placed in both sides of the shuttlebox
for the same amount of time, but no shock will be administered. Following
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training, both groups of mice will be euthanized and their brain tissue dissected
out and prepared for mRNA analysis.

Assessment of BDNF mRNA Levels
mRNA isolation: mRNA will be isolated using the Oligotex Direct mRNA Mini Kit
(Qiagen, Valencia, CA) according to the manufacturers’ protocol. Tissue will be
placed using a RNA Stabilization Reagent (Qiagen) immediately following
dissection. The mRNA concentration will be determined by spectroscopic
measurements (OD at 260 nm), using NanoDrop® ND-1000 spectrophotometer
(Isogen Life Sciences). Purified mRNA will be stored in 10 µl aliquots at -80oC
cDNA synthesis: 10ng of mRNA from each sample will be reverse transcribed
using oligo dT primers and M-MLV reverse transcriptase (Invitrogen). Reverse
transcription reactions are carried out in 20 µL following the manufacturer’s
protocol. Briefly, a 10 µL reaction mixture containing 10 ng mRNA, 1µL oligo
dT(500µg/ml), 1µL dNTP mix (10mM each) is heated at 65 0C for 5 minutes and
chilled on ice for 5 minutes, followed by addition of 1 µL (200 units) M-MLV
reverse transcriptase, 1 µL RNaseOUT (40 units/µL), 2µL DTT (0.1M) and sterile
RNAase free water to 20µL. The whole reaction mixture is incubated at 37 0C for
50 minutes, then 75 0C for 10 minutes to inactivate the enzyme. The synthesized
cDNA is stored at -20 0C before use.
The suitability of the cDNA for PCR is determined using 2uL of cDNA added to a
40 µL PCR reaction, containing primers specific for mouse BDNG exonVI (see
below and Preliminary Results). The primers amplify a 150 bp DNA segment. A
control reaction containing 2µl of purified mRNA is run without reverse
transcription to confirm the DNA contamination, if any, in the purified mRNA
samples.

The PCR reaction is analyzed on a 2% (w/v) agarose gel.

The

amplified 150bp DNA band can be excised, gel purified using a gel extraction kit
(Qiagen) and sequenced to confirm the specificity of the primers used.
Primers: Oligonucleotide sequences specific to mouse BDNF Exon I- VI and β
Actin were designed using primer Express software (Applied Biosystems) and
are given below (5′→3′ sequence):
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EXON

SENSE

ANTISENSE

I

CCTGCATCTGTTGGGGAGAC

GCCTTGTCCGTGGACGTTTA

II

CTAGCCACCGGGGTGGTGTAA

AGGATGGTCATCACTCTTCTC

III

GCCGGGCCGGATG

CCGTGGACGTTTACTTCTTTC

IV

CAGAGCAGCTGCCTTGATGTT

GCCTTGTCCGTGGACGTTTA

V

TTGGGGCAGACGAGAAAGCGC AGGATGGTCATCACTCTTCTC

VI (total)

CAGGTGAGAAGAGTGATGACC

ATTCACGCTCTCCAGAGTCCC

β Actin

Forward

CCATCATGAAGTGTGACGTGG

β Actin

Reverse

GTCCGCCTAGAAGCATTTGCG

Forward primers specific for the upstream exons will be designed in a similar
manner and used with the reverse BDNF primer for exonVI, or, if needed, a
newly designed reverse primer for exonVI.
The primer concentration is optimized for use in real time PCR to determine the
minimum primer concentration giving the lowest Ct (threshold cycle) while
minimizing nonspecific amplification. Briefly in a 96 well plate with each
amplification in triplicates of 20µL reaction containing 10 µL 2X SYBR green
Master mix and a variable concentration of forward and reverse primers is run
with thermal cycling parameters as initial step of Ampli Taq gold activation (hold
at 95oC for 10 min) followed by 40 cycles of denaturation (hold at 95oC for 10
sec) and annealing (hold at 60oC for 1 min). PCR products are analyzed on 2%
(w/v) agarose gels.
Quantitative Real-time PCR assay: Real time PCR will be carried out in a Gene
Amp 7700 sequence detection system (Applied Biosystems) using SYBR Green
Master Mix Kit (Applied Biosystems). Amplification will be performed in triplicates
in a 96-well plate(MicroAmp™ Fast Optical 96-well Reaction plates and
MicroAmp™ Optical Adhesive Film, both from Applied Biosystmes) in a total of
20µL reaction containing forward and reverse primers (100nM each final
concentration) ,10 µL Power Sybr® Green PCR Master Mix reaction buffer
(Applied Biosystems) and 2µL cDNA . The cycling parameters are 950C for 15
Sec, 60 0C for 1 min, 40 cycles after one initial step of 950C for 10 min, which is
set to activate AmpliTaq Gold polymerase. The PCR products are monitored by
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measuring the increase in fluorescence caused by binding of SYBR Green Dye
to the double stranded DNA and Ct values (cycle threshold) are calculated by
SDS software v1.9 (Applied Biosystems). The absence of nonspecific
amplification is confirmed by analyzing PCR products by 2% (w/v) agarose gel.
The relative quantification of the BDNF gene in different tissue samples is done
using a comparative method. β actin is used as endogenous control to
standardize the amount of DNA added to the reaction. Each analysis requires 6
reactions (3 for analysis of the target BDNF and 3 for analysis of the internal
standard, actin). The ∆Ct per FASD and saccharin control sample is calculated
and linearized using 2-∆Ct. Finally ∆∆Ct between treated and control samples is
calculated and linearized using 2-∆∆Ct for overall change. Thus, the amount of
target BDNF gene in the FASD mouse normalized to an endogenous reference
(β actin) and relative to control saccharin treated BDNF gene is given by an
arithmetic formula.

Results
Levels of mRNA BDNF (exons 4, 5, 8) in the HPC and MFC of both experimental
LH and control animals were measured and analyzed against a standard curve.
The results were analyzed with a T test (Table 1). As described above, ∆∆Ct
between treated and control samples was calculated and linearized using 2-∆∆Ct
for overall change.
Since BDNF levels are significantly reduced in the medial frontal cortices of
depressed patients as well as in several studies looking at depression in rodents,
we anticipated that mRNA levels would also be reduced in the brain tissue of LH
mice compared to controls. This data is consistent with the hypothesis as
indicated in figure 1. LH shocked mice displayed significantly higher levels of
learned helpless behavior than the control mice. Figure 1 shows that compared
to control mice, LH mice had significantly reduced levels of exons V [MFC,
t(6)=10.41; HPC, t(6)=4.07] and VIII [MFC, t(6)=26.8; HPC, t(6)=9.854]
(* indicates p<0.01); ie mRNA BDNF levels were significantly decreased in the
medial frontal cortex and hippocampus of LH mice compared to control mice for
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exons 5 and 8. The difference seen in exon 4 was an increase in mRNA levels as
compared to exons 5 and 8.
Further results indicated a greater decrease in BDNF mRNA in medial frontal
cortical brain regions when compared to hippocampal regions also in Figure 1.
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Figure 1. Mouse mRNA BDNF. Boxes represent exons and lines connect splice
variants.

Levels of mRNA BDNF total and specific mRNA transcripts in the

medial frontal cortex and hippocampal formation of control and Learned
Helplessness mice.
Exon 4
2.0

MFC

HPC

Control
LH

2-ΔΔCt

1.5
1.0
0.5
0.0

Exon 5
HPC

MFC

1.5

Control
LH

1.0

2-ΔΔCt

*
*

0.5

0.0

Exon-8
1.5

HPC

MFC

Control
LH

2-ΔΔCt

1.0

*

0.5

*
0.0

Control

LH

Control

LH

10

Table 1. T test analysis of BDNF exons.
Exon

Analysis
HPC not significant

4

MFC t(6)=4.4 p<0.005
HPC t(6)= 4.07 p=0.0066

5

MFC t(6)= 10.41 p<0.0001
HPC t(6) 9.854 p<0.0001

8

MFC t(6) 26.08 p<0.0001

Exon 8 measures all BDNF transcripts.
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Conclusion
In our study, we predicted that induction of depression using Learned
Helplessness would result in a decrease in the mRNA levels of one or more of
the BDNF transcripts. We further predicted that the decrease in BDNF message
will be greater in tissue taken from the medial frontal cortical region compared
with hippocampal tissue due to the role that the medial frontal cortex plays in
depression. To test this hypothesis, we measured mRNA message for the BDNF
transcript variants in both hippocampus and medial frontal cortex in mice that had
previously experienced inescapable shocks during Learned Helplessness (LH)
training. We then compared them to control mice that did not experience the
learned helplessness training.
Our results as shown in Figure 1 indicate that as predicted the LH mice
had reduced levels of mRNA in both exon 5 and exon 8.

As previously

discussed, exon 8 is a measure of the total BDNF mRNA. The fact that there is a
reduction in the amount of exon 8 is consistent with prior data that BDNF mRNA
is low in concordance with depression and learned helplessness (Karege 2002).
In addition, exons 4 and 5 were analyzed because of their precision when utilized
as primers and the ability to measure these individual exons more accurately.
The amount of BDNF exon 5 in this experiment was decreased as well.
However, it is interesting to note that the amount of BDNF exon 4 is increased.
Although exon 4 is increased, total BDNF mRNA (ie exon 8) is decreased overall.
It is possible that other exons may have yielded similar results to exon 4,
however additional exons were not analyzed in this experiment. Further study
may be needed to analyze specific exons and the effects of Learned
Helplessness on individual components of mRNA. It may be concluded that
analyzing the exons as a sum rather than individually is appropriate as individual
exons may increase in order to compensate for decreases in alternative exons to
yield a total BDNF product. Total BDNF (exon 8) was studied as it yields the
most accurate data when analyzing effects of Learned Helplessness on mice.
As predicted, the decrease in BDNF message was more substantial in
tissue taken from the medial frontal cortical region compared with hippocampal
tissue due to the role that the medial frontal cortex plays in depression. Deficits

12

in the MFC region have been identified in depressed patients via functional
neuroimaging which correlates with depressive symptoms (Drevets 2007).
Deficits in patients are appreciated in mediating emotional experience, mood,
emotional processing, and the impact of these factors on cognition. The
hippocampus, as indicated by our results was affected in addition to the MFC
and there is an indicated decrease in BDNF. This is consistent with previous
studies in which evidence is given regarding a neurotrophic hypothesis of
antidepressant action on depression. Research from Song et al (2006) states
that treatment with antidepressants improves both the changes of behavior and
hippocampus BDNF levels induced by learned helplessness and chronic mild
stress.
Serum BDNF levels can be measured in patients with major depressive
disorder (MDD), and there is a correlation between reduced BDNF levels and the
severity of depression. More specifically, low BDNF levels correlate with Major
Depressive Disorder. The model of Learned Helplessness allows for analysis of
depressed patients via mice which at this current time is the most accurate model
for depression.

In several studies conducted by Song et al. (2006), the

hypothesis that treatments with antidepressants improve both the changes of
behavior and hippocampus BDNF levels induced by Learned Helplessness was
supported. This is consistent with previous data and the data outlined in this
experiment. At this time, research is attempting to solve the question of whether
depression results secondary to diminished BDNF levels, or a reduction in BDNF
levels occurs as a result of individuals becoming depressed. This is important
information for patients, as additional knowledge of the function as well as levels
of BDNF is useful when analyzing the effects of antidepressant treatment. This
in turn will allow for further research in determining effective medications for
patients in the future. Further research is needed to analyze the individual BDNF
mRNA strands as it is currently unknown whether one specific exon may be more
essential in moderating BDNF products than alternative exons. It is possible that
there exists a more substantial response to treatment in certain patients because
of single nucleotide polymorphisms and specific BDNF transcripts. It is hopeful
that the mysteries of BDNF are elucidated in the future, but regardless, BDNF
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remains a key component of depression and Learned Helplessness, and is
essential to understanding the neurobiology of depression.

14

References
Apfel SC. (1997) Apfel Clinical Applications of Neurotrophic Factors, Lippincott–
Raven Press, Philadelphia, PA.
Caldarone BJ, George TP, Zachariou V, Picciotto MR. (2000) Gender differences
in learned helplessness behavior are influenced by genetic background.
Pharmacol Biochem Behav 66: 811-817
Chao MV. (2003) Neurotrophins and their receptors: a convergence point for
many signaling pathways. Nat Rev Neurosci. 4: 299-309.
Chen B, Dowlatshani D, MacQueen GM, Wang J-F, Young LT. (2001) Increased
hippocampal BDNF immunoreactivity in subjects treated with antidepressant
medication. Biol Psychiatry 50: 260-265.
Connor B, Young D, Yan Q, Faull RLM, Synek B, Dragunow M. (1997) Brainderived neurotrophic factor is reduced in Alzheimer's disease. Molecular Brain
Research 49: 71–81.
Drevets, Wayne C. (2007) Orbitofrontal cortex function and structure in
depression. Ann N Y Acad Sci. 1121:499-527.

Duman RS, Heninger GR, Nestler EJ. (1997) A molecular and cellular theory of
depression. Archives of General Psychiatry 54: 597–605.
Durany N, Michel T, Kurt J, Cruz-Sanchez FF, Cervas-Navarro J, Riederer P.
(2000) Brain-derived neurotrophic factor and neurotrophin-3 levels in Alzheimer's
disease brains. International Journal of Developmental Neuroscience 18: 807–
813.

15

Dwivedi Y, Mondal AC, Payappagoudar GV, Rizavi HS. (2005)

Differential

regulation of serotonin (5HT)2A receptor mRNA and protein levels after single
and repeated stress in rat brain: role in learned helplessness behavior.
Neuropharmacology. 48:204-214.
Dwivedi Y, Rizavi HS, Pandey GN.
corticosterone-mediated

decrease

in

(2006)

Antidepressants reverse

brain-derived

neurotrophic

factor

expression: differential regulation of specific exons by antidepressants and
corticosterone. Neuroscience 139: 1017-1029.
Karege F, et al. Decreased serum brain-derived neurotrophic factor levels in
major depressed patients (2002). Psychiatry Research. 109: 143-148.
Karege F, Vaudan G, Schwald M, Perroud N, La Harpe R. (2005) Neurotrophin
levels in postmortem brains of suicide victims and the effects of antemortem
diagnosis and psychotropic drugs. Mol Brain Res 136: 29-37.
Liu Q-R, Lu L, Zhu X-G, Gong J-P, Shaham Y, Uhl GR. Rodent BDNF genes,
novel promoters, novel splice variants, and regulation by cocaine. Brain Res
1067: 1-12.
Lu B, Pang PT, Woo NH (2005). The yin and yang of neurotrophin action.
Nature.
Mamounas LA, Blue ME, Siuciak JA, Altar CA. (1995) Brain-derived neurotrophic
factor promotes the survival and sprouting of serotonergic axons in rat brain.
Journal of Neuroscience 15: 7929–7939.
Monteggia LM, Luikart B, Barrot M, Theobold D, Malkovska I, Nef S, Parada LF,
Nestler EJ. (2006) Brain-Derived Neurotrophic Factor Conditional Knockouts
Show Gender Differences in Depression-Related Behaviors. Biol Psychiatry

16

Mowla SJ, Farhadi HF, Pareek S, Atwal JK, Morris SJ, Seidah NG, Murphy RA.
(2001) Biosynthesis and post-translational processing of the precursor to brainderived neurotrophic factor. J Biol Chem. 276:12660-12666.
Nibuya M, Morinabu S, Duman S. (1995) Regulation of BDNF and trkB mRNA in
rat brain by chronic electroconvulsive seizure and antidepressant drug
treatments. Journal of Neuroscience 15: 7539–7547.
Okazawa H, Muarata M, Watanabe M, and Kanazawa I. (1992) Dopaminergic
stimulation up-regulates the in vivo expression of brain-derived neurotrophic
factor (BDNF) in the striatum. FEBS Letters 313: 138–142.
Seidah NG, Benjannet S, Pareek S, Chretien M, Murphy RA (1996) Cellular
processing of the neurotrophin precursors of NT3 and BDNF by the mammalian
proprotein convertases. FEBS Lett. 379:247-250.
Song L, Che W, Min-Wei W, Murakami Y, Matsumoto K. (2006) Impairment of
the spatial learning and memory induced by learned helplessness and chronic
mild stress. Pharmacol Biochem Behav 83: 186-193.
Takahashi M, Shirakawa O, Toyooka K, Kitamura N, Hashimoto T, Maeda K,
Koizumi S, Wakabayashi K, Takahashi H, Someya T, Nawa H. (2000) Abnormal
expression of brain-derived neurotrophic factor and its receptor in the
corticolimbic system of schizophrenic patients. Molecular Psychiatry 5: 293–300.
Timmusk T, Palm K, Metsis M, Reintam T, Paalme V, Saarma M, Persson H.
(1993)

Multiple promoters direct tissue-specific expression of the rat BDNF

gene. Neuron 10: 475-489.

17

